Fig. 4From: Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR statusa Adenocarcinoma characterized by a heterogeneous MLH1 status in a tumour with complete loss of MSH2/MSH6. b-c Areas of complete loss of MSH2/MSH6 in a pMMR background. d A pMMR mucinous adenocarcinoma coexisting with a synchronous dMMR low-grade tubular adenoma. Scale bar indicates 100 μmBack to article page